WHAT HAS HAPPENED RECENTLY IN NICE?
What has happened recently in NICE?
If you want to get up to date news from NICE they have a news page
with the latest information.
Guidance and Quality standards in the process of development
What is coming up?
APCP is asking members for their comments
on some draft guidance, so take a look and see if you might be interested to submit some comments.
Children and young people with disabilities and severe complex needs: integrated health and social care support and service guidance
02 August 2021 - 14 September 2021.
We need your comments by 4 September
– please email titling subject as above
and send them to: email@example.com
Expected final publication of guidance documents on 19 January 2022
Consultation coming soon …
Epilepsies in children, young people and adults (previously separate guidelines on epilepsies in children and young people, and epilepsies in adults)
NICE have published the plan for development of this guidance – you can see the review questions, search strategy and their economic plan here
expected 24 September 2021
- 05 November 2021, so we will be asking APCP members for comments in an extra bulletin.
Expected publication of final guidance document 09 March 2022
Final Guidance soon to be published…
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and
management: Full update
APCP member Joanne Bond Kendall is on the committee. Guidance consultation
ended on 22 December and the guideline will now publish on 18 August 2021
Babies, children and young people’s experience of healthcare
The draft guidance consultation
was recently completed.
You can read about it in this article
and find more documents here
. The publication date for the completed guidance is expected to be Wednesday 25 August 2021
. Quality standards will then be developed.
Other guidance in process of being developed:
Rehabilitation for Chronic Neurological Disorders Including Traumatic Brain Injury
This will include children and young people. The draft scope consultation closed on 6 July and can be read here
. The final scope document from which the committee will develop the guidance should be published shortly, the work of the committee will then start and the final guidance document is to be published on 02 August 2023.
The final scope
document setting out what the guidance will cover can be found here
An APCP member took part in the scoping workshop and presented comments from a large group of APCP members with interest and expertise in this area. Some physiotherapists applied to be on the guidance development committee and are waiting to hear if any of them were successful. The draft guidance document is expected to be opened for comments around 23 December 2022.
Fetal alcohol spectrum disorder
Quality standard consultation
has been completed. These include standards regarding
neurodevelopmental assessment and provision of a management programme. The consultation
closed on 20 September. The publication date is TBC.
Head injury: assessment and early management
–the final scope for the guidance has been
. It very much looks at the immediate care: re-hospital interventions, transport directly to a neuroscience centre, assessment and management in the emergency department and discharge and follow up, including follow up of people with normal scans for deterioration, people with asymptomatic small intracranial injuries and people with post-concussion syndrome.
This is now in committee being developed. The draft guidance will be open for comments from 22 December 2021 - 26 January 2022.
Recent publications that may be of interest….
There is a new single guideline for managing COVID-19 in children and adults
This guideline brings together existing recommendations on managing COVID-19 in children, young people and adults in all care settings. It includes new recommendations on therapeutics and replaces our COVID-19 rapid guidelines on:
• critical care in adults
• managing symptoms (including at the end of life) in the community
• managing suspected or confirmed pneumonia in adults in the community
• acute myocardial injury
• antibiotics for pneumonia in adults in hospital
• acute kidney injury in hospital
• reducing the risk of venous thromboembolism in over 16s with COVID-19
Spinal Muscular Atrophy Type 1
A new and potentially curative one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE. NICE’s draft guidance published on 8 March 2021 recommends £1.79 million treatment Zolgensma also called onasemnogene abeparvovec) for babies
aged up to 12 months with type
New NICE Guidance on Bronchiolitis published!
The new guidance document: Bronchiolitis in children: diagnosis and management refers to the role of physiotherapy:
1.4.1Do not perform chest physiotherapy on babies and children with bronchiolitis who do not have relevant comorbidities (for example spinal muscular atrophy, severe tracheomalacia).
1.4.2Consider requesting a chest physiotherapy assessment in babies and children who have relevant comorbidities (for example spinal muscular atrophy, severe tracheomalacia) when there may be additional difficulty clearing secretions.
For more information see
School based interventions: physical and mental health and wellbeing promotion
Quality standards consultation delayed and TBC. Expected publication TBC
APCP NICE officer